NCT04322318 2026-02-24
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Children's Oncology Group
Phase 2 Recruiting
Clinical Trials
32 trialsNCT05137262 2026-02-18
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT04383743 2025-09-18
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Phase 2 Completed
NCT02710734 2024-12-24
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT02177695 2024-09-19
COXEN
SWOG Cancer Research Network
Phase 2 Completed
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT00068393 2023-07-07
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003683 2021-02-21
Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer
UNICANCER
Phase 2 Completed
NCT00478361 2020-10-09
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02560051 2018-11-28
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT02494713 2018-11-27
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00080782 2018-10-31
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00307294 2017-11-24
Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
University of Pittsburgh
Phase 2 Completed
NCT00335556 2017-07-21
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Children's Oncology Group
Phase 2 Completed
NCT00630409 2017-03-10
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT00416533 2017-01-19
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
Wake Forest University Health Sciences
Phase 2 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00808639 2016-10-24
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00506155 2016-03-31
Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00635726 2015-10-08
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00176293 2015-04-21
Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer
University of Kentucky
Phase 2 Terminated
NCT00005960 2013-12-04
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00025103 2013-08-02
Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002919 2013-07-03
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01095926 2013-06-28
Doxo
University Hospital Muenster
Phase 2 Completed
NCT00002466 2013-06-20
Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00014352 2013-01-16
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00080795 2012-10-22
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003084 2012-07-30
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003640 2012-03-06
Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated